Mvabea

Modified Vaccinia Ankara - Bavarian Nordic virus encoding Ebola virus Zaire Mayinga strain glycoprotein, the active ingredient in Mvabea, is a vaccine presented as a sterile injectable for intramuscular use. It is designed to prevent Ebola virus disease caused by the Zaire strain in individuals at risk of exposure.

GNH USA supplies Mvabea as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, and clinics worldwide, with established cold‑chain logistics and regulatory support for global distribution, ensuring product integrity and timely delivery to end‑users.

Mvabea is a recombinant viral vector vaccine that targets the Ebola virus Zaire strain and is used for prophylaxis in at‑risk populations. - Ebola virus disease (Zaire strain) prevention: induces immunity to protect against infection. - Healthcare workers in outbreak zones: reduces occupational risk of Ebola acquisition. - Travelers to endemic regions: provides pre‑exposure protection against Ebola virus.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or swelling: localized erythema or edema. - Fever: transient low‑grade temperature rise. - Headache: mild to moderate headache within 24‑48 hours. - Fatigue: temporary feeling of tiredness. - Myalgia: muscle aches after vaccination.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Guillain‑Barré syndrome: rare neurologic disorder with progressive weakness. - Severe thrombocytopenia: marked drop in platelet count. - High‑grade fever >39 °C: prolonged febrile response. - Seizures: uncommon convulsive episodes. - Disseminated intravascular coagulation: rare clotting disorder.

Before administration, consider the following precautions: - Contraindication assessment: avoid in individuals with known severe allergic reaction to any vaccine component. - Immunocompromised patients: evaluate risk‑benefit as immune response may be reduced. - Acute illness: defer vaccination if the person has a moderate or severe febrile illness. - Pregnancy and lactation: discuss potential risks with a qualified health professional. - Age restrictions: follow local regulatory guidance for eligible age groups. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Vaccines may interact with other agents that affect the immune system. Major Interactions (Avoid): - Live attenuated vaccines administered concurrently: may interfere with immune response to Mvabea. - High‑dose immunoglobulin therapy given within 4 weeks: can diminish vaccine efficacy. Moderate Interactions (Monitor Closely): - Immunosuppressive drugs (e.g., corticosteroids, chemotherapy): may reduce immunogenicity. - Antipyretics taken prophylactically: may blunt antibody response if used before vaccination. - Antihistamines: may mask early allergic signs; monitor patient closely after injection.